Get the Stockscreener App
24.12
2.20%
0.52
After Hours:
24.40
0.28
+1.16%
Arcutis Biotherapeutics Inc stock is traded at $24.12, with a volume of 1.39M.
It is up +2.20% in the last 24 hours and down -7.52% over the past month.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
See More
Previous Close:
$23.60
Open:
$23.45
24h Volume:
1.39M
Relative Volume:
0.88
Market Cap:
$2.95B
Revenue:
$317.93M
Net Income/Loss:
$-44.32M
P/E Ratio:
-68.04
EPS:
-0.3545
Net Cash Flow:
$-48.24M
1W Performance:
-10.70%
1M Performance:
-7.52%
6M Performance:
+48.80%
1Y Performance:
+80.00%
1-Day Range:
$22.85
$24.56
1-Week Range:
$22.85
$28.80
52-Week Range:
$11.86
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
24.12 | 2.89B | 317.93M | -44.32M | -48.24M | -0.3545 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Arcutis (ARQT) Earnings Call Signals Scaled Growth - TipRanks
Insider Sell Alert: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus
Arcutis (ARQT) director sells 39,272 shares under 10b5-1 plan - Stock Titan
Vanguard Group Inc. Buys 96,991 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 3,687 Shares - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) CFO Latha Vairavan Sells 2,853 Shares - MarketBeat
Patrick Burnett Sells 6,287 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 37,349 Shares of Stock - MarketBeat
Arcutis (NASDAQ: ARQT) CFO gets RSU, option grants and sells shares - Stock Titan
Arcutis (ARQT) director Watanabe sells shares and receives large option, RSU awards - Stock Titan
Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial By Investing.com - Investing.com Australia
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New Trial Launch And Upgraded Revenue Outlook - simplywall.st
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis - Bitget
Arcutis Biotherapeutics Begins Enrollment for Phase 1a/1b Atopic Dermatitis Study - marketscreener.com
Arcutis Biotherapeutics (ARQT) Begins Phase 1 Study of ARQ-234 - GuruFocus
Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial - Investing.com
New Arcutis trial tests immune-checkpoint drug for atopic dermatitis - Stock Titan
Targets Report: Can Arcutis Biotherapeutics Inc deliver consistent EPS growth2025 Institutional Moves & Stock Timing and Entry Methods - baoquankhu1.vn
Masaru Matsuda reports Rule 144 share sales for Arcutis Biotherapeutics (NASDAQ: ARQT) - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) insider sale notice: 3,687 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 37,349 shares after vesting - Stock Titan
Mizuho cuts Arcutis stock price target to $35 on higher costs - Investing.com UK
Arcutis Biotherapeutics (ARQT) insider sale notice: 10,000 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 6.9% After Analyst Downgrade - MarketBeat
ARQT: Mizuho Lowers Price Target but Maintains Outperform Rating - GuruFocus
Mizuho Has Lowered Expectations for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price - MarketBeat
Research Analysts Offer Predictions for ARQT Q1 Earnings - MarketBeat
Precision Trading with Arcutis Biotherapeutics Inc. (ARQT) Risk Zones - Stock Traders Daily
ARQT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Arcutis Biotherapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ARQT) 2026-02-27 - Seeking Alpha
Arcutis execs join TD Cowen health care conference March 2-4 - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $35.00 at Guggenheim - MarketBeat
Guggenheim Raises Price Target for ARQT to $35 | ARQT Stock News - GuruFocus
Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative? - Yahoo Finance
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Issues Pessimistic Outlook for ARQT Earnings - MarketBeat
Arcutis Management to Present at TD Cowen's 46th Annual Health Care Conference - Bitget
TD Cowen Raises Target Price for Arcutis Biotherapeutics (ARQT) to $35 | ARQT Stock News - GuruFocus
Arcutis Biotherapeutics (NASDAQ:ARQT) Given New $35.00 Price Target at TD Cowen - MarketBeat
Forecasting The Future: 4 Analyst Projections For Arcutis Biotherapeutics - Benzinga
Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case - Seeking Alpha
ARQT: HC Wainwright & Co. Raises Target Price to $34 in Latest A - GuruFocus
Needham raises Arcutis stock price target to $36 on strong sales - Investing.com Nigeria
H.C. Wainwright raises Arcutis stock price target on strong Zoryve sales - Investing.com Nigeria
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Arcutis Biotherapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Price Target Raised by Needham | - GuruFocus
Earnings call transcript: Arcutis Biotherapeutics Q4 2025 beats expectations By Investing.com - Investing.com Australia
Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT In - GuruFocus
Arcutis Biotherapeutics Inc (ARQT) Q4 2025 Earnings Call Highlig - GuruFocus
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):